SRR12696750
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.500
- CHOLESTEROL_HOMEOSTASIS+0.500
- ESTROGEN_RESPONSE_EARLY+0.500
- ESTROGEN_RESPONSE_LATE+0.500
- P53_PATHWAY+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- ADIPOGENESIS+0.300
- APOPTOSIS+0.300
- FATTY_ACID_METABOLISM+0.300
- MYOGENESIS+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.300
- INTERFERON_ALPHA_RESPONSE-0.200
- PANCREAS_BETA_CELLS-0.200
- COMPLEMENT-0.100
- DNA_REPAIR-0.100
- E2F_TARGETS-0.100
- G2M_CHECKPOINT-0.100
- IL6_JAK_STAT3_SIGNALING-0.100
- MITOTIC_SPINDLE-0.100
- SPERMATOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8f45c6c4-b98d-4e0b-9bb0-b5be3894076d | — | — | 0.782 |
| 2 | BS_196BBNEJ | EPN | Posterior Fossa EPN | 0.758 |
| 3 | BS_196BBNEJ | Posterior Fossa Ependymoma | — | 0.743 |
| 4 | BS_4Y6BCYK5 | pilocytic astrocytoma | — | 0.730 |
| 5 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.716 |
| 6 | SRR23303744 | — | — | 0.703 |
| 7 | MBCproject_0253_T1_RNA | — | B | 0.702 |
| 8 | s0112232 | — | — | 0.701 |
| 9 | R38 | — | — | 0.700 |
| 10 | SRR8613716 | — | C | 0.698 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.500 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.500 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.500 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.500 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.400 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |